Safety and Efficacy of LVD + C-TACE + Tis/Len for Unresectable Right-Liver HCC

Condition(s) studied

Investigational drug(s) / intervention(s)

Liver Venous Deprivation (LVD): Simultaneous embolization of the right portal vein and right hepatic vein to induce FLR hypertrophy.

Conventional Transarterial Chemoembolization(C-TACE): Conventional TACE performed using Lipiodol and chemotherapy agents (Epirubicin/Oxaliplatin)

Tislelizumab combined with Lenvatinib: Tislelizumab 200 mg administered intravenously every 3 weeks (Q3W) + 8 mg (for weight \<60 kg) or 12 mg (for weight ≥60 kg) orally once daily (QD)

Study summary

This study evaluates a novel "Dual-Conversion" strategy (mechanical volume conversion via LVD plus biological conversion via cTACE, Tislelizumab, and Lenvatinib) for patients with initially unresectable right-sided hepatocellular carcinoma (HCC). The primary goal is to assess the rate of successful conversion to R0 resection and the safety profile of this multi-modal approach.

Eligibility

Primary outcome measure(s)

• Conversion-to-Surgery Rate — From enrollment to the end of treatment at 12 weeks
  The proportion of patients who successfully undergo R0 resection after receiving the dual-conversion therapy

Trial sites (1)